Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Agency Tests Remote Inspections Program To Identify At-Risk GDP Sites

Executive Summary

The UK Medicines and Healthcare products Regulatory Agency is testing a new remote, office-based inspection process, in place of physical inspections, to assess risk at “satellite sites” that perform a limited number of good distribution practice-related activities for companies.

You may also be interested in...



COVID-19: UK MHRA Says Non-Essential Inspections Will Be Office-Based

The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.

Global Medtech Guidance Tracker: March 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.

UK MHRA Finds Labs Releasing Unreliable Data Due To Pressure From Pharma

A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule. 

Topics

UsernamePublicRestriction

Register

PS125157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel